2. Academic Validation
  3. Intravitreal injection of cell membrane-coated nanoparticles for retinoblastoma treatment

Intravitreal injection of cell membrane-coated nanoparticles for retinoblastoma treatment

  • J Control Release. 2025 Jun 6:385:113939. doi: 10.1016/j.jconrel.2025.113939.
Yichi Zhang 1,  Kaiqi Long 1,  Ka Yi Lee 2,  Jia Li 1,  Shuting Xu 1,  Kang Chen 2,  Xi Chen 1,  Qingyi Dai 3,  Yifan Lin 4,  Changyou Zhan 5,  Weiping Wang 6
Affiliations

Affiliations

  • 1 State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China.
  • 2 State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China.
  • 3 State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China; Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China.
  • 4 Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China.
  • 5 Department of Pharmacology, School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200032, China.
  • 6 State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China. Electronic address: wangwp@hku.hk.
PMID: 40484284 DOI: 10.1016/j.jconrel.2025.113939
Abstract

Chemotherapy is a widely adopted treatment for malignant intraocular tumors such as retinoblastoma. However, achieving high delivery efficiency remains challenging due to rapid clearance and lack of targeting specificity. Cancer cell membrane-coated nanoparticles have been extensively reported to exhibit specific affinity to homotypic Cancer cells. Here we designed poly (lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles coated with the plasma membrane of WERI-Rb-1 cells, derived from human retinoblastoma. These nanoparticles showed remarkable affinity to WERI-Rb-1 cells in vitro. Loaded with the FDA-approved chemotherapy drug etoposide, the nanoparticles exhibited excellent antitumor efficacy and excellent biosafety following a single-dose intravitreal injection in vivo. Overall, this work presents a simple yet effective strategy for the treatment of retinoblastoma.

Keywords

Cell membrane-coated nanoparticles; Homotyic targeting; Intraocular drug delivery; Intravitreal injection; Retinoblastoma.

Figures
Products
Inhibitors & Agonists
Other Products